MyoKardia, Inc. is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

Our initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. 

About Cardiomyopathies

Heartbeats: A Conversation with The Hypertrophic Cardiomyopathy Experts

News & Events

March 17, 2017
MyoKardia Appoints Kim Popovits and Wendy Yarno to Board of Directors

March 13, 2017
MyoKardia Reports Fourth Quarter and Full Year 2016 Financial Results and Operational Progress

February 2, 2017
First Subjects Dosed in MyoKardia Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491

February 1, 2017
MyoKardia Announces Appointment of June Lee, M.D., as Chief Operating Officer and Radhika Tripuraneni, M.D., as Vice President, Medical Affairs

January 3, 2017
MyoKardia Announces Advancement to Next Phase of Global Collaboration with Sanofi